QureBio’s Q-1802 Clinical Application Accepted by NMPA

News

}

Home / News / Portfolio Highlights / Portfolio Highlights detail

Time: 2020-12-30

Source: Viva Biotech

[Abstract]:The first Claudin 18.2/PD-L1 bispecific antibody drug accepted by NMPA.

SHANGHAI, CHINA---- Recently, QureBio (Shanghai) Co., Ltd. (hereinafter referred to as QureBio), which is invested and incubated by Viva BioInnovator and focused on the R&D of innovative macromolecular biopharmaceuticals, announced that the Center for Drug Evaluation, NMPA, has accepted the clinical trial application of its recombinant anti-Claudin 18.2 and PD-L1 humanized bispecific antibody for injection (code: Q-1802) according to "Category 1 of Therapeutic Biological Novel Products".

Official data shows that Q-1802 is the first Claudin 18.2/PD-L1 bispecific antibody drug accepted by NMPA.

Previous Page：The U.S. Food and Drug Administration granted IND approval for Q-1802 Next Page：Xlement Attended 3rd China International Import Exhibition

Back

Media contact: vivapr@vivabiotech.com

This site uses cookies and your privacy choices are important to us

We use cookies to improve the user experience and to analyze website traffic. By clicking "Accept", you consent to the use of cookies on our website, such as cookies policies.